<DOC>
	<DOCNO>NCT01734993</DOCNO>
	<brief_summary>This multicenter , open-label , single arm , interventional , long-term extension ( LTE ) study evaluate safety efficacy tocilizumab ( TCZ , RoActemra/Actemra ) French participant moderate severe RA complete Week 97 visit WA22762 LTE study ( NCT01194414 ) ( EudraCT Number 2010-018375-22 ) . Participants France , complete Week 97 visit WA22762 LTE study consider responder ( define improvement disease activity score base 28-joint count [ DAS28 ] great [ &gt; ] 1.2 point ) continue TCZ treatment within local LTE study maximum 156 week subcutaneous ( SC ) TCZ treatment , SC TCZ become commercially available , whichever occur first .</brief_summary>
	<brief_title>A Long-Term Extension Study WA22762 Evaluate Safety Efficacy Subcutaneous Tocilizumab Participants With Moderate Severe Rheumatoid Arthritis ( RA ) .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Negative pregnancy test screen baseline Participants complete 97week WA22762 LTE study SC intravenous ( IV ) TCZ experience , time WA22762 , clinically significant improvement DAS28 ( &gt; 1.2 point ) , base investigator 's judgment may continue benefit TCZ treatment study investigate SC formulation No current recent adverse event laboratory finding prevent use study drug dose TCZ 162 mg SC baseline visit Receiving treatment outpatient basis Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception study least 3 month follow last dose study drug Oral corticosteroid nonsteroidal antiinflammatory drug ( NSAIDS ) recommend dose permitted stable dose regimen great equal ( &gt; /= ) 4 week prior baseline Permitted nonbiological diseasemodifying antirheumatic drug ( DMARDs ) allow Participants prematurely withdraw WA22762 LTE study reason Previous treatment celldepleting therapy , include investigational agent approve therapy Treatment antitumor necrosis factor ( TNF ) antiinterleukin ( IL ) 1 agent , Tcell co stimulation modulator since last administration study drug WA22762 LTE study Immunization live/attenuated vaccine since last administration study drug WA22762 LTE study Diagnosis , since last WA22762 visit ( Week 97 ) , rheumatic autoimmune disease rheumatoid arthritis ; secondary Sj√∂rgen 's syndrome RA permit Diagnosis , since last WA22762 visit ( Week 97 ) , inflammatory joint disease RA Uncontrolled disease state , asthma inflammatory bowel disease , flare commonly treated oral parenteral corticosteroid Evidence serious uncontrolled concomitant disease Known active current history recurrent infection Primary secondary immunodeficiency ( history currently active ) Body weight &gt; 150 kilogram ( kg ) Pregnant lactate woman Inadequate hematologic , renal liver function History alcohol , drug chemical abuse within 1 year prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>